지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.87 No.2
- 발행연도
- 2014.7
- 수록면
- 72 - 80 (9page)
이용수
초록· 키워드
오류제보하기
Purpose: The aim of this study was to compare the therapeutic effects of radiofrequency ablation (RFA) and hepatic resection (HR) with regards to procedural morbidity, mortality, overall survival (OS) and disease-free survival (DFS) rates in hepatocellular carcinoma (HCC) patients.
Methods: Retrospective studies were performed based on the medical records of 129 patients who underwent curative HR, and 57 who patients received RFA for HCC, between 2005 and 2009. The inclusion criteria of HCC were the presence of three or fewer nodules 3 cm or less in diameter or a single nodule of 5 cm or less.
Results: The 1-, 3- and 5-year OS rates in the HR group were 91.3%, 78.8%, and 64.9%, compared to 94.4%, 74.0%, and 74.0% in the RFA group, with no significant difference between the two groups (P = 0.725). The estimated 1- and 3-year DFS rates were 70.0% and 53.0% in the HR group and 65.2% and 24.7% in the RFA group, respectively. The DFS rates of HR group were significantly higher than RFA group (P = 0.015). Multivariate analysis identified that recurrence (P = 0.036) and portal hypertension (P = 0.036) were associated with OS and that portal hypertension (P = 0.048) and increased serum a-FP (P = 0.008) were the factors significantly associated with DFS.
Conclusion: HCC within Milan criteria should consider hepatectomy as the primary treatment if the patient"s liver function and general conditions are good enough to undergo surgical operation. But in that RFA revealed similar overall survival to HR, RFA can be an alternative therapy for patients who are eligible for surgical resection.
Methods: Retrospective studies were performed based on the medical records of 129 patients who underwent curative HR, and 57 who patients received RFA for HCC, between 2005 and 2009. The inclusion criteria of HCC were the presence of three or fewer nodules 3 cm or less in diameter or a single nodule of 5 cm or less.
Results: The 1-, 3- and 5-year OS rates in the HR group were 91.3%, 78.8%, and 64.9%, compared to 94.4%, 74.0%, and 74.0% in the RFA group, with no significant difference between the two groups (P = 0.725). The estimated 1- and 3-year DFS rates were 70.0% and 53.0% in the HR group and 65.2% and 24.7% in the RFA group, respectively. The DFS rates of HR group were significantly higher than RFA group (P = 0.015). Multivariate analysis identified that recurrence (P = 0.036) and portal hypertension (P = 0.036) were associated with OS and that portal hypertension (P = 0.048) and increased serum a-FP (P = 0.008) were the factors significantly associated with DFS.
Conclusion: HCC within Milan criteria should consider hepatectomy as the primary treatment if the patient"s liver function and general conditions are good enough to undergo surgical operation. But in that RFA revealed similar overall survival to HR, RFA can be an alternative therapy for patients who are eligible for surgical resection.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (30)
참고문헌 신청
1. [학술지(정기간행물)] - Bosch FX. / 1999 / Epidemiology of primary liver cancer / Semin Liver Dis 19 : 271 ~ 285
2. [보고서] - Ministry of Health & Welfare / 2008 / Annual report of cancer incidence (2005) and survival (1993-2005) in Korea
3. [학술지(정기간행물)] - Bosch FX. / 2005 / Epidemiology of hepatocellular carcinoma / Clin Liver Dis 9 : 191, 211, ~ 211, v
4. [학술지(정기간행물)] - Bruix J. / 2001 / Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver / J Hepatol 35 : 421 ~ 430
5. [학술지(정기간행물)] - Livraghi T. / 2001 / Guidelines for treatment of liver cancer / Eur J Ultrasound 13 : 167 ~ 176
2. [보고서] - Ministry of Health & Welfare / 2008 / Annual report of cancer incidence (2005) and survival (1993-2005) in Korea
3. [학술지(정기간행물)] - Bosch FX. / 2005 / Epidemiology of hepatocellular carcinoma / Clin Liver Dis 9 : 191, 211, ~ 211, v
4. [학술지(정기간행물)] - Bruix J. / 2001 / Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver / J Hepatol 35 : 421 ~ 430
5. [학술지(정기간행물)] - Livraghi T. / 2001 / Guidelines for treatment of liver cancer / Eur J Ultrasound 13 : 167 ~ 176
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2015-510-002473358